Trial Profile
Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Nigerian Children
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Pneumococcal 10-valent vaccine conjugate (Primary)
- Indications Otitis media; Pneumococcal infections; Pneumonia
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 14 Oct 2016 New trial record